Psilocybin Drug Shows Promise for Depression

Big news in the mental health world: Compass Pathways’ psilocybin therapy just hit a major milestone in a Phase III trial for treatment-resistant depression. Patients on COMP360 saw a real drop in depression scores compared to placebo, and the results are strong enough for the FDA to take notice. While the company kept some details under wraps (like full placebo data), analysts say the effect size is more than enough for the next regulatory steps. Psychedelics in medicine might be closer than we think! #MentalHealth #DepressionTreatment #Psychedelics #Health